U.S. Markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.90 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.44 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.53
    -0.18 (-0.39%)
     
  • Gold

    1,788.10
    -23.10 (-1.28%)
     
  • Silver

    22.64
    -0.81 (-3.44%)
     
  • EUR/USD

    1.1970
    +0.0057 (+0.4788%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3314
    -0.0042 (-0.3169%)
     
  • USD/JPY

    104.0850
    -0.1650 (-0.1583%)
     
  • BTC-USD

    18,118.26
    +350.21 (+1.97%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

Chemed's Roto-Rooter & VITAS Robust, Acuity Mix Shift Weak

Zacks Equity Research

On Jul 15, we issued an updated research report on Chemed Corporation CHE. The company currently operates two wholly-owned subsidiaries, namely VITAS Healthcare and Roto-Rooter.

Over the past three months, shares of Chemed have consistently outperformed its industry. The stock has gained 9.5% compared with the industry’s 3.5% rise. Chemed exited 2018 on a promising note. The company generated strong year-over-year growth in revenues. It is optimistic to note that it witnessed a solid revenue uptick across its key subsidiaries.

VITAS has been registering an expanded average daily census. Moreover, the Roto-Rooter business has been seeing growth on the back of a solid performance by the core plumbing and drain cleaning service segments as well as a robust trend in water restoration.

Moreover, we are upbeat about Roto-Rooter, which is currently the nation's leading provider of plumbing and drain cleaning services. Through its network of company-owned branches, independent contractors and franchises, Roto-Rooter offers plumbing and drain cleaning services to more than 90% of the U.S. population.

Chemed Corporation Price

Chemed Corporation Price
Chemed Corporation Price

Chemed Corporation price | Chemed Corporation Quote

On the flip side, Chemed ended first-quarter 2019 on a dull note. Both earnings and revenues missed the respective Zacks Consensus Estimate in the reported quarter. An unfavorable acuity mix shift, fluctuations in net room and board plus contractual adjustments dented the top line during the period.

Chemed's capital deployment policy is based on its suitable buyouts and a solid return of cash to shareholders through dividends and buybacks. 

Zack Rank and Key Picks

Chemed currently curries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are Teleflex Inc. TFX, Penumbra PEN and NuVasive Corporation NUVA. While Teleflex currently carries a Zacks Rank #2 (Buy), the other two sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Teleflex’s long-term earnings growth rate is expected at 13.7%.

Penumbra’s long-term earnings growth rate is projected at 21.5%.

NuVasive’s long-term earnings growth rate is expected to be 11.9%.

Radical New Technology Creates $12.3 Trillion Opportunity

 Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors. Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.

See the 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Teleflex Incorporated (TFX) : Free Stock Analysis Report
 
Penumbra, Inc. (PEN) : Free Stock Analysis Report
 
NuVasive, Inc. (NUVA) : Free Stock Analysis Report
 
Chemed Corporation (CHE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.